Ratings Sonendo, Inc.

Equities

SONX

US8354311073

Market Closed - OTC Markets Other stock markets 20:58:11 03/05/2024 BST			5-day change	1st Jan Change
0.1049 ^USD	-0.10%		+9.27%	-50.05%

04-10	Sonendo, Inc. Announces Sadie Stern Not to Stand for Reelection to the Board of Directors	CI
03-13	North American Morning Briefing : Stock Futures -2-	DJ

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SONENDO, INC.	-50.05%	7.39M	-
ABBOTT LABORATORIES	-3.79%	184B	C+
MEDTRONIC PLC	-0.84%	108B	C
BECTON, DICKINSON AND COMPANY	-3.75%	67.8B	A
DEXCOM, INC.	+3.45%	51.05B	B-
CENCORA, INC.	+9.04%	44.67B	B-
HOYA CORPORATION	+3.40%	41.78B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B	A-
TERUMO CORPORATION	+15.23%	25.86B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes